CClinicalTrials.gg
CompletedNCT03958500ANSCRSUpdated Jun 3, 2022

The Problem of Colorectal Anastomosis Safety

An interventional study of Indocyanine green fluorescent angiography intraluminally and intraperitoneally in Colorectal Cancer, Colorectal Carcinoma and Colorectal Neoplasms, sponsored by Vilnius University. Completed at 2 sites in Lithuania. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-06-03.

Sponsored by Vilnius University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This is a prospective cohort pilot study. The investigators are planning to develop an original, standardized colorectal anastomosis inspection method, which will systemically inspect the anastomosis vascularity using the indocyanine green fluorescent angiography intraluminally and intraperitoneally, the air leak test, the methylene blue test, the tension in the anastomosis inspection, patients' risk factors scale sum. The summarized evaluation will determine the final anastomotic leak risk.

02

Conditions studied

  • Colorectal Cancer
  • Colorectal Carcinoma
  • Colorectal Neoplasms
  • Colorectal Adenocarcinoma
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's enrollment of 60 is below the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Vilnius University is the lead sponsor of 60 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patients over 18 year
  • signed written consent
  • a colorectal anastomosis lower 15 cm from anal verge
  • elective surgery

Exclusion criteria

Exclusion Criteria:

  • allergy to indocyanine green dye
  • pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Comprehensive anastomotic testing

    All patients undergo: 1. Indocyanine green fluorescent angiography intraluminally and intraperitoneally 2. Air leak test 3. Methylene blue test

    Procedure: Indocyanine green fluorescent angiography intraluminally and intraperitoneally

Interventions

  • ProcedureIndocyanine green fluorescent angiography intraluminally and intraperitoneally

    The use of indocyanine green fluorescent angiography to check bowel and anastomosis viability in standard low anterior rectal anastomosis

    Also known as: Air leak test, Methylene blue test

06

What researchers measure

Primary outcomes

  1. Rate of anastomotic leakage

    The number of patients, who had clinical or radiological anastomotic leakage. Proctography will be performed 6-8 days and 4-6 weeks after the primary operation.

    Time frame: 0 to 60 days

Secondary outcomes

  1. Quality of life before and after the operation

    Using low anterior resection syndrome score (the LARS score - simple 5 question questionnaire). LARS score is a tool consisting of five items, which are as follows: incontinence due to flatus (score range from 0 to 7), incontinence due to liquid stools (score range from 0 to 3), frequency of bowel movements (score range from 0 to 5), clustering (score range from 0 to 11) and urgency (score range from 0 to 16). The severity of each item is calculated on a scale ranging from 0 to 42, with a score of 0-20 (no LARS), 21-29 (minor LARS) and 30-42 (major LARS).

    Time frame: 0 to 60 days

  2. Quality of life before and after the operation

    Using QLQ-C30 questionnaire. To compare change in Quality of Life, as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30 (Version 3)) before operation and 4-6 weeks after the operation. The EORTC QLQ-C30 (Version 3) uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome. The EORTC QLQ-C30 (Version 3) uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome.

    Time frame: 0 to 60 days

  3. Reoperation rate

    Patients, who needed re-interventions

    Time frame: 0 to 60 days

  4. Intraoperative test leakage

    Leakage rate detected intraoperatively after anastomosis testing

    Time frame: 0 to 600 minutes

  5. Time of anastomosis testing

    Time from the start of the anastomosis testing till the end

    Time frame: 0 to 600 minutes

  6. Operation time

    Time from the start of the operation until the end of the operation

    Time frame: 0 to 600 minutes

  7. 90 days mortality

    the mortality of the patients after the operation

    Time frame: 0 to 90 days

  8. Timing of anastomosis leakage

    In days after surgery

    Time frame: 0 to 60 days

07

Study locations

2 sites
  • National Cancer Institute, Vilnius, Lithuania
    Vilnius, Lithuania
  • Vilnius University hospital Santaros klinikos
    Vilnius, Lithuania
08

References and documents

Publications

  • Kryzauskas M, Poskus E, Dulskas A, Bausys A, Jakubauskas M, Imbrasaite U, Makunaite G, Kuliavas J, Bausys R, Stratilatovas E, Strupas K, Poskus T. The problem of colorectal anastomosis safety. Medicine (Baltimore). 2020 Jan;99(2):e18560. doi: 10.1097/MD.0000000000018560. PubMed 31914032 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03958500
Lead sponsor
Vilnius University
Collaborators
Vilnius University hospital Santaros klinikos, Vilnius, Lithuania, National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Responsible party
Marius Kryzauskas (Principal investigator, Vilnius University) — Principal investigator
First posted
May 22, 2019
Start date
Apr 1, 2019
Primary completion
Dec 30, 2021
Completion
Jan 31, 2022
Last update
Jun 3, 2022

Study contacts

Eligijus Poskus, prof.
principal investigator · Vilnius University, Vilnius, Lithuania

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion